PURPOSE: The aim of this study was to evaluate the effect of CPAP treatment on the health related quality of life (QOL)in patients with obstructive sleep apnea syndrome (OSAS).
METHODS: A group of 35 OSAS patients (30 male and 5 female, mean age 51±12 years, mean body mass index 35.6±8 Kg/m2) who were diagnosed with polysomnography study (criteria for OSAS: AHI≥5 and daytime symptoms), and treated with CPAP for 6 months. The health related quality of life was assessed by administering an officially validated (Cronbach's a statistic>0.7) Greek version of the Sleep Apnea Quality of Life Index (SAQLI) while sleepiness was assessed by the Epworth Sleepiness Scale (ESS). The statistical analysis of the results, which were obtained before the CPAP application and 6 months after CPAP, was made using the paired t-test method with the level of significance set at 95% (p=0.05).
RESULTS: Our results concerning the comparison of the QOL parameters before and after CPAP (mean value ± standard deviation) with the corresponding level of significance are presented as following: SAQLI (3.8 ±1.0 before CPAP vs. 5.9±0.8 after CPAP, p<0.01), section of daily functioning (4.4 ±1.5 vs.6.1±0.9, p<0.01), section of social interactions (4.8 ±1.4 vs.6.4±0.8, p<0.01), section of emotional functioning (4.6±1.4 vs.5.9±1.1, p<0.01), section of symptoms (1.6±1.1 vs.6.1±1.3, p<0.01) and ESS (14.1±6.5 vs. 3.8±3.9, p<0.01). Body mass index (BMI) was also reduced after CPAP treatment (35.6±8.0 vs. 34.3±7.5, p<0.05). All patients (35/35) reported a substantial improvement of their quality of life after six months of CPAP treatment.
CONCLUSION: CPAP treatment in OSAS results in a steady and significant improvement of the quality of life. Furthermore, CPAP improves daytime sleepiness of OSAS patients and it seems that it also may help them to loose weight.
CLINICAL IMPLICATIONS: CPAP treatment has substantially beneficial effects on obstructive sleep apnea syndrome and OSAS patients’ general health.
DISCLOSURE: Irene Avlonitou, No Financial Disclosure Information; No Product/Research Disclosure Information